source
- GSK says UK restructuring will have limited impact on staff, focusing cuts on support rolesGSK executives said the company's global restructuring will only modestly affect UK staff, mainly targeting support functions at headquarters. CEO Luke Miels explained during the Q3 earnings call…
- Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trialThe highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.BioPharma Dive · 22d ago↗ source